DOXIMITY INC-CLASS A (DOCS) Fundamental Analysis & Valuation
NYSE:DOCS • US26622P1075
Current stock price
24.57 USD
-0.09 (-0.36%)
At close:
24.9378 USD
+0.37 (+1.5%)
After Hours:
This DOCS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. DOCS Profitability Analysis
1.1 Basic Checks
- In the past year DOCS was profitable.
- DOCS had a positive operating cash flow in the past year.
- Each year in the past 5 years DOCS has been profitable.
- In the past 5 years DOCS always reported a positive cash flow from operatings.
1.2 Ratios
- DOCS has a Return On Assets of 20.69%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
- With an excellent Return On Equity value of 24.45%, DOCS belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
- DOCS has a Return On Invested Capital of 19.48%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 7.46%.
- The last Return On Invested Capital (19.48%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 24.45% | ||
| ROIC | 19.48% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
- DOCS's Profit Margin of 37.54% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
- DOCS's Profit Margin has improved in the last couple of years.
- With an excellent Operating Margin value of 37.44%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Operating Margin of DOCS has grown nicely.
- DOCS's Gross Margin of 89.75% is amongst the best of the industry. DOCS outperforms 97.06% of its industry peers.
- DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.44% | ||
| PM (TTM) | 37.54% | ||
| GM | 89.75% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. DOCS Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DOCS is creating value.
- DOCS has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, DOCS has more shares outstanding
- DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- DOCS has an Altman-Z score of 17.51. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
- DOCS has a Altman-Z score of 17.51. This is amongst the best in the industry. DOCS outperforms 94.12% of its industry peers.
- DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 17.51 |
ROIC/WACC1.96
WACC9.93%
2.3 Liquidity
- A Current Ratio of 6.63 indicates that DOCS has no problem at all paying its short term obligations.
- DOCS has a better Current ratio (6.63) than 94.12% of its industry peers.
- DOCS has a Quick Ratio of 6.63. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
- DOCS has a better Quick ratio (6.63) than 94.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.63 | ||
| Quick Ratio | 6.63 |
3. DOCS Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 28.91% over the past year.
- The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
- DOCS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.92%.
- DOCS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.42% yearly.
EPS 1Y (TTM)28.91%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%2.22%
Revenue 1Y (TTM)15.92%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%9.76%
3.2 Future
- The Earnings Per Share is expected to grow by 9.29% on average over the next years. This is quite good.
- The Revenue is expected to grow by 8.79% on average over the next years. This is quite good.
EPS Next Y11.83%
EPS Next 2Y8.39%
EPS Next 3Y9.35%
EPS Next 5Y9.29%
Revenue Next Year13.75%
Revenue Next 2Y11.26%
Revenue Next 3Y10.65%
Revenue Next 5Y8.79%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. DOCS Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 14.89, the valuation of DOCS can be described as correct.
- Based on the Price/Earnings ratio, DOCS is valued cheaper than 82.35% of the companies in the same industry.
- DOCS is valuated rather cheaply when we compare the Price/Earnings ratio to 26.91, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 14.83, the valuation of DOCS can be described as correct.
- Based on the Price/Forward Earnings ratio, DOCS is valued cheaper than 82.35% of the companies in the same industry.
- DOCS is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.99, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.89 | ||
| Fwd PE | 14.83 |
4.2 Price Multiples
- DOCS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 67.65% of the companies in the same industry.
- 76.47% of the companies in the same industry are more expensive than DOCS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.77 | ||
| EV/EBITDA | 12.51 |
4.3 Compensation for Growth
- DOCS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.26
PEG (5Y)0.19
EPS Next 2Y8.39%
EPS Next 3Y9.35%
5. DOCS Dividend Analysis
5.1 Amount
- No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
DOCS Fundamentals: All Metrics, Ratios and Statistics
24.57
-0.09 (-0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Industry Strength0.62
Industry Growth47.21
Earnings (Last)02-05 2026-02-05/amc
Earnings (Next)05-19 2026-05-19/amc
Inst Owners93.18%
Inst Owner Change0.88%
Ins Owners2.17%
Ins Owner Change0.24%
Market Cap4.54B
Revenue(TTM)637.78M
Net Income(TTM)239.40M
Analysts81.33
Price Target41.08 (67.2%)
Short Float %11.56%
Short Ratio5.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.81%
Min EPS beat(2)1.21%
Max EPS beat(2)16.41%
EPS beat(4)4
Avg EPS beat(4)17.96%
Min EPS beat(4)1.21%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)20.77%
EPS beat(12)12
Avg EPS beat(12)20.67%
EPS beat(16)16
Avg EPS beat(16)21.74%
Revenue beat(2)1
Avg Revenue beat(2)2.2%
Min Revenue beat(2)-0.43%
Max Revenue beat(2)4.82%
Revenue beat(4)3
Avg Revenue beat(4)2.07%
Min Revenue beat(4)-0.43%
Max Revenue beat(4)4.82%
Revenue beat(8)6
Avg Revenue beat(8)3.12%
Revenue beat(12)8
Avg Revenue beat(12)2.38%
Revenue beat(16)11
Avg Revenue beat(16)1.96%
PT rev (1m)-7.16%
PT rev (3m)-38.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.99%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.06%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-4.21%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.89 | ||
| Fwd PE | 14.83 | ||
| P/S | 7.12 | ||
| P/FCF | 14.77 | ||
| P/OCF | 14.39 | ||
| P/B | 4.63 | ||
| P/tB | 5.3 | ||
| EV/EBITDA | 12.51 |
EPS(TTM)1.65
EY6.72%
EPS(NY)1.66
Fwd EY6.74%
FCF(TTM)1.66
FCFY6.77%
OCF(TTM)1.71
OCFY6.95%
SpS3.45
BVpS5.3
TBVpS4.64
PEG (NY)1.26
PEG (5Y)0.19
Graham Number14.0296 (-42.9%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 24.45% | ||
| ROCE | 23.71% | ||
| ROIC | 19.48% | ||
| ROICexc | 72.13% | ||
| ROICexgc | 130.98% | ||
| OM | 37.44% | ||
| PM (TTM) | 37.54% | ||
| GM | 89.75% | ||
| FCFM | 48.17% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 62.82% | ||
| Cap/Sales | 1.29% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 125.24% | ||
| Profit Quality | 128.33% | ||
| Current Ratio | 6.63 | ||
| Quick Ratio | 6.63 | ||
| Altman-Z | 17.51 |
F-Score7
WACC9.93%
ROIC/WACC1.96
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)28.91%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%2.22%
EPS Next Y11.83%
EPS Next 2Y8.39%
EPS Next 3Y9.35%
EPS Next 5Y9.29%
Revenue 1Y (TTM)15.92%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%9.76%
Revenue Next Year13.75%
Revenue Next 2Y11.26%
Revenue Next 3Y10.65%
Revenue Next 5Y8.79%
EBIT growth 1Y6.94%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.92%
EBIT Next 3Y11.19%
EBIT Next 5Y9.2%
FCF growth 1Y90.12%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y89.16%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS Fundamental Analysis FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 8 / 10 to DOCS.
What is the valuation status for DOCS stock?
ChartMill assigns a valuation rating of 6 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
Can you provide the profitability details for DOXIMITY INC-CLASS A?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What is the valuation of DOXIMITY INC-CLASS A based on its PE and PB ratios?
The Price/Earnings (PE) ratio for DOXIMITY INC-CLASS A (DOCS) is 14.89 and the Price/Book (PB) ratio is 4.63.